Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05268887 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 1, 2025 to Nov 1, 2027 Completion date: Nov 2025 to Nov 2027 · Site contact updatedv7 Show 2 more changesShow less
    • Completion date: Nov 2025 to Nov 2027
    • Site contact updated
  2. Primary completion date: Nov 2024 to Nov 1, 2025 Site contact updatedv6 Show 1 more changeShow less
    • Site contact updated
  3. Re-verified, no change to tracked fieldsv5
  4. Site contact updatedv4
  5. Primary completion date: Mar 2023 to Nov 2024 Completion date: Nov 2023 to Nov 2025 · Site contact updatedv3 Show 2 more changesShow less
    • Completion date: Nov 2023 to Nov 2025
    • Site contact updated
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Parkinson's disease (PD) impacts different types of neural oscillations in the brain, including beta (13-30Hz) and gamma oscillations (30-80Hz), which contributes to PD's cardinal symptoms of resting tremor, rigidity, bradykinesia (slowness of movement), and gait instability. The investigators' lab has developed a non-invasive method of increasing gamma power in the brain using Gamma Entrainment Using Sensory Stimulation (GENUS) through light, sound, and tactile stimulation devices. For this study, 40 participants with mild Parkinson's disease will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) before, during, and after light, sound, and tactile stimulation to determine the safety, feasibility, and optimization of GENUS as a potential therapy in the PD population.
Trial Details
NCT Number NCT05268887
Lead Sponsor Massachusetts Institute of Technology
Conditions Parkinson Disease
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov